Servier and Cellectis sign $850m cancer collaboration
This article was originally published in Scrip
Servier has signed a strategic collaboration agreement with Cellectis to develop and commercialize up to six cancer products in a deal potentially worth $850m.
You may also be interested in...
A Phase I study for allogeneic therapy UCARTCS1A was put on clinical hold after a patient died. High dosing and double exposure to cyclophosphamide pre-conditioning may have played a role.
Servier SA has moved to broaden its immune-oncology pipeline by signing a license and collaboration agreement for the development, manufacture and commercialization of products using Sorrento Therapeutics Inc.'s anti-PD-1 monoclonal antibody (mAb) STI-A1110, adding to its ongoing CAR-T efforts.
China's WuXi PharmaTech, an R&D technology company serving the pharmaceutical, biotechnology and medical device industries, has announced construction of a new manufacturing facility in Philadelphia, US designed for cell therapy products, including chimeric antigen receptor T-cell (CAR-T) therapies. More manufacturing power is crucial to the success of this burgeoning, high-potential field.